Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why ImmuPharma plc (LSE:IMM) Evaluates Subcutaneous Bioavailability Profiles for Autoimmune Peptide Candidates in the FTSE AIM All-Share

A pivotal strategic milestone for ImmuPharma was achieved through the receipt of a highly supportive Combined Search and Examination Report from the United Kingdom Intellectual Property Office concerning its P140 auto-immune patent filings. Building upon this positive regulatory evaluation, the company has progressed international …

Ankur Sharma | 16 November 2026

What Chill Brands Group PLC (LSE:CHLL) Outlined for Automated Order Routing Across Independent Convenience Retailers

The cornerstone of Chill Brands' operational repositioning centres on its proprietary Chill Connect distribution model. Under this revised framework, the company has deployed a dedicated field sales network servicing independent convenience retailers across the United Kingdom. Rather than relying solely on third-party wholesale brokers, …

Ankur Sharma | 16 November 2026

What Cambridge Nutritional Sciences PLC (LSE:CNSL) Reported on Reagent Lot Consistency Across Diagnostic Kits in the FTSE AIM All-Share

The primary technological and commercial driver for Cambridge Nutritional Sciences (LSE:CNSL) is its proprietary Foodprint microarray platform. Designed to quantify food-specific immunoglobulin G (IgG) antibody reactions across extensive dietary panels, Foodprint enables accredited clinical laboratories and private healthcare clinics to process high-throughput diagnostic samples …

Ankur Sharma | 16 November 2026

What Coiled Therapeutics Plc (LSE:COIL) Reported Concerning Preclinical Pharmacodynamic Biomarker Selection

The operational focus of Coiled Therapeutics involves utilizing advanced cellular assays, high-throughput phenotypic screening, and computational structural biology to optimize lead chemical series. By collaborating with leading academic institutions and specialized specialist contract organisations (CROs), the company screens small-molecule compounds for biochemical potency, target …

Ankur Sharma | 16 November 2026

Why Creo Medical Group Plc (LSE:CREO) Focuses on Bipolar Radiofrequency Coagulation Control in Endoscopic Devices in the FTSE AIM All-Share

The flagship commercial instrument within Creo's surgical suite is the Speedboat Inject, a specialised endoscopic device engineered for endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of precancerous gastrointestinal lesions. By integrating tissue dissection, precise vessel coagulation, and needle-free liquid submucosal injection into …

Ankur Sharma | 16 November 2026

What ConvaTec Group Plc (LSE:CTEC) Disclosed Regarding Continence Care Catheter Coating Friction Reduction as a FTSE 100 Constituent

The engine of ConvaTec's organic revenue growth is its accelerated R&D pipeline, highlighted by proprietary foam and antimicrobial dressing platforms. The company's flagship Aquacel Ag+ Extra dressings utilize patented Hydrofiber technology combined with ionic silver to manage wound exudate and disrupt pathogenic biofilms in …

Ankur Sharma | 16 November 2026

Why Diaceutics Plc (LSE:DXRX) Focuses on Real-Time Biomarker Testing Gap Analytics for Pharma Launches in the FTSE AIM All-Share

The engine of Diaceutics' corporate growth is its proprietary DXRX platform, an end-to-end commercialisation platform that integrates laboratory diagnostic data from hundreds of clinical testing laboratories worldwide. Pharmaceutical companiesMarketingtargeted oncology, autoimmune, and rare disease therapeutics subscribe to DXRX to gain real-time visibility into diagnostic …

Ankur Sharma | 16 November 2026

How ECO Animal Health Group plc (LSE:EAH) Manages Regional Regulatory Renewal Dossiers for Aivlosin in the FTSE AIM All-Share

Recognising global regulatory shifts and consumer demands to curb veterinary antimicrobial usage in commercial farming, ECO Animal Health has aggressively pivoted R&D resources toward preventative biological vaccines. The group is developing novelVaccineplatforms targeting major livestock pathogens, including Mycoplasma hyopneumoniae in swine and avian respiratory …

Ankur Sharma | 16 November 2026

How EKF Diagnostics Holdings plc (LSE:EKF) Optimises Point-of-Care Haemoglobin Cuvette Manufacturing Tolerances in the FTSE AIM All-Share

The group's operational architecture is built upon two complementary commercial pillars: Core Point-of-Care Diagnostics and Life Sciences Contract Manufacturing. In point-of-care, EKF supplies proprietary analysers—including the Hemo-Control and DiaSpect haemoglobin meters—generating recurring, high-margin revenues from disposable microcuvettes and reagent strips. Simultaneously, its Life Sciences …

Ankur Sharma | 16 November 2026

What EMV Capital PLC (LSE:EMVC) Reported Regarding Fair Value Uplifts Across Life Sciences Portfolio Holdings in the FTSE AIM All-Share

The core asset base of EMV Capital (LSE:EMVC) comprises shareholdings across innovative portfolio companies spanning point-of-care diagnostics, digital health, robotics, and clean technology. Key investee companies include PDS Biotechnology (targeted immunotherapies), ProAxsis (respiratory protease diagnostics), and robotic automation innovators. By actively participating on investee …

Ankur Sharma | 16 November 2026
Support

Hi! How can we help you today?

Loading…